1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1985
Current Management of Hodgkin’s Disease
Behrens B, Young R, DeVita V. Current Management of Hodgkin’s Disease. Drugs 1985, 30: 355-367. PMID: 3905335, DOI: 10.2165/00003495-198530040-00004.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's diseaseDurable complete remissionAcute side effectsCombination chemotherapy programsLong-term complicationsPrognosis of patientsImproved treatment approachesProbable cureInduction therapySalvage therapyMost patientsTerm complicationsChemotherapy programSuch patientsStandard radiotherapySpecific therapySide effectsTreatment approachesPatientsCurrent managementCurrent trialDiseaseTherapyRemission
1973
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses